Chloroquine
- TRADE NAMES: Aralen (Sanofi-Aventis); Avloclor; Chlorquin; Emquin; Heliopar; Lagaquin; Malarivon
- INDICATIONS: Malaria, rheumatoid arthritis, lupus erythematosus
- CLASS: Antimalarial, Antiprotozoal, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 3–5 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acitretin, Antacids, Arsenic, Cholera Vaccine, Cholestyramine, Citalopram, Dapsone, Dasatinib, Degarelix, Droperidol, Ethosuximide, Furazolidone, Halofantrine, Hydroxychloroquine, Lacosamide, Lanthanum, Lapatinib, Levofloxacin, Methotrexate, Methoxsalen, Mivacurium, Moxifloxacin, Neostigmine, Nilotinib, Oxcarbazepine, Pazopanib, Penicillamine, Ribociclib, Sulfonamides, Telavancin, Telithromycin, Tiagabine, Typhoid Vaccine, Vandetanib, Vigabatrin, Voriconazole, Vorinostat, Ziprasidone
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
OTIC
RESPIRATORY
OTHER
Page last updated 09/01/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
